CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

Bristol-Myers Squibb's financial position improved, it raised both its EPS guidance and revenue expectations, and Opdivo's ...

Misinterpretation of MRI findings by clinicians focused on earlier intervention is leading to increased rates of ...

Combined with the last dividend raise by +3.3% in December 2024, building upon the 10Y growth profile at +5.27%, we believe ...

Most patients with psoriasis experienced clinical improvement or remission after metabolic and bariatric surgery (MBS) in a ...

This was the stock's third consecutive day of gains.

By Sriparna Roy (Reuters) -Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of ...

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The stock's fall snapped a four-day winning streak.

A look at the shareholders of Bristol-Myers Squibb Company (NYSE:BMY) can tell us which group is most powerful. With 81% ...

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Goldman Sachs 46 th Annual Global Healthcare Conference on Wednesday, June 11, 2025. The company will take ...